CLINICAL STUDY PROTOCOL  
Study ID  ADVM -022-04 
Study Title  A Phase 2, Multi -Center, Randomized, Double -Masked, 
Active Controlled Study of ADVM -022 (AAV.7m8-
aflibercept) in Subjects with Diabetic Macular Edema 
[INFINITY ] 
Indication Studied  Diabetic Macular Edema (DME ) 
Sponsor  Adverum Biotechnologies, Inc.  
[ADDRESS_374218] 
Redwood City, CA [ZIP_CODE] 
Protocol Version Document Identifier  / Effective Date 
Original  ADVM -022-04 / 19 March 2020  
Amendment 1.0  
Amendment 2.0 Amendment 3.0  
Amendment 4.0  
Amendment 5.0  
Amendment 6.0  
Amendment 7.0  ADVM -022-04 v1.0 / 16 April 2020  
ADVM -022-04 v2.0 / 04 May  2020 
ADVM -022-04 v3.0 / 02 September 2020 
ADVM -022-04 v4.0 / 17 February 2021 
ADVM -022-04 v5.0 / 04 May 2021 
ADVM -022-04 v6.0 / 14 July 2021 
ADVM -022-04 7.0 / [ADDRESS_374219]/Ethics 
Committee. This information cannot be used for any other purpose othe r than the evaluation or conduct of the 
clinical study without the prior written consent of Adverum Biotechnologies Inc.  
1 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
A-DVERUM 
BIOTECHNOLOGIES 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374220]  2021 
 CONFIDEN TIAL  Page 2 of 74 INVESTIGATOR AGREEMENT  
Study ID  ADVM -022-04 
Study Title  A Phase 2, Multi -Center, Randomized, Double -Masked , 
Active Control led, Study of ADVM -022 (AAV.7m8-
aflibercept) in Subjects with Diabetic Macular Edema 
[INFINITY] 
Version  Amendment 7.0, [ADDRESS_374221] Study ADVM -022-04 in compliance with the terms of the protocol as outlined 
herein and in compliance with Good Clinical Practice (GCP) and al l applicable legal and 
regulatory requirements.  Furthermore, I understand that the Sponsor, Adverum Biotechnologies, 
Inc. (Adverum), and the Institutional Review Board /Institutional Biosafety Committee 
(IRB/IBC) must approve any changes to the protocol in  writing before implementation, except 
where it may be necessary to eliminate an immediate hazard to a subject enrolled in this study.  I 
agree not to divulge to anyone, either during or after the study, any confidential information acquired regarding the investigational medicinal product and processes or methods of Adverum.  
All data pertaining to this study will be provided to Adverum.    
   
Principal Investigator (signature)   Date  
Printed Name:   
[CONTACT_16277]:   
  
2 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374222] 
Redwood City, CA [ZIP_CODE] 
Sponsor’s Medical Monitor    
Medical Director  
phone:  
email:  
SAE Reporting  Phone:  
 
  
Fax:  
 
  
Email:
  
 
 
3 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Advernm Biotechno logies , Inc. ADVM-022 (AA V.7m8 -aflibercept) 
Protocol No. ADVM-022 -04 (Amendmen t 7.0) 
Adverum Biotechnologi es, Inc. 
Clinical Protocol No. ADVM-022-04 ADVM- 022 (AA V.7m8-aflibe1 ·cept) 
Amendment 7.0, [ADDRESS_374223] 2021 
PROTOCOLAPPROVAL-ADVERUM SIGNATORY 
Study ID 
Study Title 
Version ADVM -022-04 
A Phase 2, Multi-Center , Randomized, Doub le-Masked, Active 
Controlled Study of ADVM -022 (AA V.7m8-aflibe rcept) in 
Subjects with Diabetic Macu lar Edema [INFINI TY] 
Amendment 7.0, 05 Augus t 2021 
Study ADVM -022-04 w ill be conducted in accordance with the International Council for 
Harmonisatio n of Technical Requ iremen ts for Pha1maceut icals for Hum an Use (ICH) and 
Harmonised T1ipaitite Guidel ines for Good Clinical Practices (E6), with applicable local 
regulatio ns (including US Code of Federa l Regulations [C FR] Title 21, and the ethical p1inciples 
outlined in the Declarat ion of H elsinki). 
Protoco l approved by: 
[CONTACT_305805] m Biotechno logies, Inc. 
Signature [CONTACT_305838] 4 of 74 
IND 0198 49 / Sequence No. 0018 CONFIDENTIAL 4 of74 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374224]  2021 
 CONFIDENT IAL Page 5 of 74 TABLE OF CONTENTS  
CLINICAL STUDY PROTOCOL ...............................................................................................1  
INVESTIGATOR AGREEMENT  ...............................................................................................2  
STUDY CONTACTS  .....................................................................................................................3  
PROTOCOL APPROVAL—AD VERUM SIGNATORY  .........................................................[ADDRESS_374225] (ADVM -022) ..................................................25  
3.3 Preclinical Summary for ADVM -022 ....................................................................26  
3.4 Other Clinical Studies of ADVM -022 ...................................................................26  
3.5 Formulation  ............................................................................................................31  
3.6 Dose Justification  ...................................................................................................31  
4.0 CLINICAL STUDY OBJECTIVES AND ENDPOINTS  .............................................32  
4.1 Objectives  ..............................................................................................................32  
4.1.1  Primary Objective  .................................................................................32  
4.1.2  Secondary Objectives  ............................................................................32  
4.2 Endpoints ...............................................................................................................33  
4.2.1  Primary Endpoints  .................................................................................33  
4.2.2  Secondary Endpoints .............................................................................33  
5.0 CLINICAL INVESTIGATION PLAN  ..........................................................................33  
5.1 Study Design ..........................................................................................................33  
5.1.1  : ...................................................34  
5.1.2  Rescue Treatment:  .................................................................................35  
5.1.3  Data Monitoring Committee (DMC):  ...................................................35  
5.1.4  Stoppi[INVESTIGATOR_1869]: .....................................................................................[ADDRESS_374226] Accountability and Reconciliation .................38  
5 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374227] SELECTION CRITERIA AND WITHDRAWAL  ....................................40  
6.1 Selection Criteria  ...................................................................................................40  
6.2 Screening Records .................................................................................................40  
6.3 Inclusion Criteria  ...................................................................................................41  
6.4 Exclusion Criteria  ..................................................................................................41  
6.4.1  General Exclusion Criteria  ....................................................................41  
6.4.2  Ocular Exclusion Criteria (Study Eye) .................................................43  
6.4.3  Ocular Exclusion Criteria (Fellow or Study Eye) .................................[ADDRESS_374228] 
(Retinal and Optional Anterior Segment Imaging) ...............................49  
7.9.2  Optional Optical Coherence Tomography Angiography (OCT- A) ......49  
7.9.3  Ultra -wide Field Fundus Photography and Iris Photography ...............49  
7.9.4  Ultra -wide Field Fluorescein Angiography ..........................................49  
7.9.5  Optional Ultrasound Biomicroscopy (UBM) ........................................50  
7.10  Laboratory, Biomarker and Other Biological Specimens  ......................................50  
7.10.1  Optional Aqueous Humor Sampling .....................................................50  
7.10.2  Optional Vitreous Humor and Other Ocular Tissue Sampling .............50  
6 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374229]  2021 
 CONFIDENTI AL Page 7 of 74 8.0 REQUIRED, CONCOMITANT AND EXCLUDED MEDICATIONS  .....................50  
8.1 Required Medications ............................................................................................50  
8.1.1   ) .......................................................................50  
8.1.2  Eylea® (aflibercept)  ...............................................................................[ADDRESS_374230] (Immediately reportable to Sponsor)  .............[ADDRESS_374231] / Institutional Biosafety Committee  ...........................[ADDRESS_374232] Information and Consent ...........................................................................60  
13.0  INVESTIGATOR’S RESPONSIBILITIES  ..................................................................60  
14.0  SPONSOR RESPONSIBILITIES  ..................................................................................61  
14.1  Modification of the Protocol ..................................................................................61  
14.2  Protocol Deviations ................................................................................................61  
14.3  Confidentiality  .......................................................................................................61  
14.4  Investi gator’s Report to the IRB/IBC  ....................................................................62  
14.5  Records Retention  ..................................................................................................62  
14.6  Financial Disclosure and Obligations ....................................................................62  
14.7  Liability and Insurance ..........................................................................................63  
14.8  Publication Policy  ..................................................................................................63  
7 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
... 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374233] OF TABLES  
Table  1: Number of Patients (Events) with ADVM -022 Related Adverse Events 
in the Study Eye by [CONTACT_305806]-022 Dose in Clinical 
Protocol No. ADVM -022- 01 [OPTIC]  ......................................................29  
Table  2:  Safety Factors of Proposed ADVM- 022 Clinical Doses for the DME 
Study Over the Safe Nonhuman Primate Dose ..........................................32  
Table  3: Study Arms ................................................................................................34  
Table  4:  ..............................................................................39  
Table  5: Power for [ADDRESS_374234] Tests at Various Rate Assumptions  ........58  
 
8 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374235]  2021 
 CONFIDEN TIAL  Page 9 of 74 1.0 STUDY SYNOPSIS  
Title of Study:  A Phase 2, Multi -Center, Randomized, Double -Masked, Active 
Controlled Study of ADVM-022 (AAV.7m8- aflibercept) in Subjects 
with Diabetic Macular Edema [ INFINITY ] 
Sponsor:  Adverum Biotechnologies, Inc.  
Phase of 
Development:  Phase 2  
Study Sites:  Appro ximately  15 sites in the [LOCATION_002]  
Objectives:  Primary Objective:  
• To assess the durability of a single intravitreal (IVT) injection of 
ADVM -022  
Secondary Objectives:  
• To assess the safety and tolerability of ADVM-022 
• To evalu
ate the effect of ADVM-022 on macular edema  
• To evalu
ate the effect of ADVM-[ADDRESS_374236] Corrected Visual 
Acuity (
BCVA)  
• To evaluate the effect of ADVM-022 on Diabetic Retinopathy 
Severity
 Scale (DRSS) score  
• To assess the need for rescue aflibercept (2  mg IVT)  
•
 To assess the effect of a preceding dose of aflibercept (2 mg IVT) 
prio
r to ADVM -022 administration  
• To evaluate the effec t of ADVM -022 on development of vision 
threatening complications ( including anterior segment 
neovascularization, vitreous hemorrhage, or tractional retinal 
detachment)  
Primary Endpoint:  • Time to worsening of DME disease activity in the study eye   
Secondary 
Endpoints:  Unless specified otherwise, the secondary endpoints are based on 
outcome measures for the study eye. 
• Incidence and severity of ocular and non-ocular adverse events (AEs)  
• Change from B aseline in  cen
 tral subfield thickness (CST)  and 
macular volume over time through Week 96 
• Change from Baseline in BCVA over time  through We ek 96    
• Frequency of r escue afliber cept (2  mg IVT) in the study eye over 
time during the study  
• Incidence of 2 -step and 3 -step improvement in DRSS score over 
time through Week  96  
9 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374237]  2021 
 CONFIDEN TIAL  Page 10 of 74 • Incidence of 2 -step and 3 -step worsening in DRSS score  over 
time through Week  96 
• Occurrence of vision threatening complications (anterior segment 
neovascularization, vitreous hemorrhage, or any other high- risk 
proliferative DR or tractional retinal detachment)  over time  through 
Week 96 
• Incidence of CST <300 μm over ti me through Week 96 
• Incidence of clinically significant findings via physical 
examinati
ons, ocular examinations, imaging, and laboratory 
evaluation 
Investigational 
Product and Dosage:  ADVM -022 (AAV.7m8 -aflibercept) investigational medicinal product 
is a genetically engineered, replication incompetent, capsid variant of the adeno-associated viral vector of serotype 2 (AAV2).  
A single 0.10 mL IVT administration of ADVM -022 will be evaluated 
at two dose levels: 2 × 1011 vg/eye and 6 × 1011 vg/eye. 
Reference Therapy : Name: [CONTACT_305839] a® (aflibercept)  
Dosage, Route, Frequency: 0.05 mL of 2 mg administered via IVT for a single injection.  
Study Design : This is a multi -center, randomized, double -masked, controlled, parallel -
group study to evaluate the efficacy, safety and tolerability of a single 
IVT injection of ADVM -022. Two doses of ADVM-[ADDRESS_374238] received up to 2 prior injections of anti- VEGF  therapy are 
eligible  for enrollment.  
Approximately 33 eligible subjects will be randomized to one of 5 arms .  Arm 1 (n=6) will receive ADVM -022 6 × 10
11 vg/eye with a 
preceding aflibercept  dose . Arm 2 (n=6) will receive ADVM -022 
6 × 1011 vg/eye of with out a preceding aflibercept dose. Arm 3 (n=6) 
will receive ADVM -022 2 ×1011 vg/eye with a preceding aflibercept  
dose. Arm 4 (n=6) will receive ADVM -022 2 × 1011 vg/eye of without a 
preceding aflibercept  dose . Arm 5 (n=9) will receive aflibercept only  
(active control) .  To maintain masking of the treatment assignment, 
subjects assigned to the arms with  no preceding aflibercept on Day [ADDRESS_374239] will be selected as the study eye.  If both eyes are eligible, the eye with the worse BCVA will be the study eye.    
10 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Advernm Biotechnolog ies, Inc. ADVM- 022 (AA V.7m8-afl ibercept) 
Protocol No. ADVM- 022-04 ( Ame ndmen t 7.0) 
Adver um Biotechnologies, Inc. 
Clinical Prot ocol No. ADVM-022-04 ADVM-022 (AA V.7m8-a flibe1 ·cept) 
Ame ndme nt 7.0, [ADDRESS_374240] 2021 
Subjec ts will be randomized to the following treatmen t aims in the 
followin g table: 
Day l Day s 
IVT Aflib ercept or IVT ADVM-022 Dose 
Arm N S ham (vg/eye) 
[ADDRESS_374241] become an open-label study, in which all prior masked roles 
will be able to continue study pruticipation in an unma sked manner. 
I 
CONF IDENTIAL Page 11 of74 
IND 019849 / S equence No. 0018 CONFIDENTIAL 11 of 74 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374242]  2021 
 CONFIDENTI AL Page 12 of 74  
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
  
 
 
  
  
  
  
  
  
 
  
 
  
 
 
 
12 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
·-I 
I 
I 
I 
Advernm Biotechnologies , Inc. ADVM-022 (AA V.7m8-afli bercept) 
Protocol No. ADVM-022 -04 (Amendmen t 7.0) 
Adverum Biotechnologies, Inc. 
Clinical Protocol No. ADVM-022-04 ADVM-022 (AA V.7m8-aflibe1 ·cept) 
Amendment 7.0, [ADDRESS_374243] 2021 
Rescue Treatment: 
Starting at Week 8, subjects will receive rescue aflibercept (2 mg IVT) 
if they meet any of the following: 
• Increa se in CST > [ADDRESS_374244] measurements recorded at Day 1 or Week 4 
• Loss of> 5 letters in BCVA due to worsening DME disease activity 
compared to the higher of the two BCVA measurements recorded at 
Day 1 or Week 4. 
After the initial rescue treatment administration, subsequent rescue 
treatment may be administered PRN per the discretion of the Primary 
Investigator. 
Only intravitreal aflibercep t injection (Eylea) is to be used for any 
rescue treatment unless prior approva l by [CONTACT_305807]. 
Aflibercep t should not be injected in eyes with active inflammatio n. A 
minimum of21 days is required between rescue aflibercep t injections. 
Independent Data Monitoring Committee (DMC) 
An independent DMC will monitor safety and study conduct on an 
ongo ing basis. Members of the DMC will be independent from the 
Sponsor and will follow a charter that outlines the DMC's roles and 
responsibi lities. The DMC will meet every 3-6 months (frequenc y 
adjustable as required) to evaluate unmasked ocular· and non-ocular 
safety events , with emphas is on the evaluation of the rate of ocular· 
inflamma tion, increased intraocu lar· pressure (IOP), endophthalm itis, 
and clinically significant decreases in BCV A. The DMC will also meet 
on an ad hoc basis if stopp ing rnles ar·e met as outlined below . The 
DMC may recommend stopp ing the study early for safety reasons. After 
reviewing the data, the DMC will provide a recommenda tion to the 
Sponsor as described in the DMC Charter. Any outcomes of these data 
CONF IDENTIAL Page 13 of74 
IND 0198 49 / Sequence No. 0018 CONFIDENTIAL 13 of74 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374245] will be communicated in a timely 
manner to the investigators for notification of their respective 
Institutional Review Boards  (IRBs) . 
Stoppi[INVESTIGATOR_1869]:  
Enrollment will be suspended if any of the following sight threatening events occur
:  
• A decrease of ≥ 30 letters in BCVA in the study eye compared with the prior vi
sit  
• A surgical intervention (i.e., conventional surgery, vitrectomy) to 
prevent p
ermanent loss of sight  
• Severe intraocular inflammation (i.e., endophthalmitis, 4+ anterior 
chamber cel
l/flare, or 4+ vitreous cells)  
In addition, enrollment will be suspended if any serious adverse event potentiall
y related to ADVM-022 occurs.  
Any event that meets any of the above safety stoppi[INVESTIGATOR_305795] a recommendation to the Sponsor. 
The regulatory authorities and the Investigator s, and each site’s IRB and 
other appropriate institutional regulatory bodies will be promptly notified if a decision to suspend enrollment is made. 
• If study enrollment is suspended, all subjects who have already been 
treated will remain in the study and will continue to be monitored through their completion or withdrawal from the study.  
Study Duration:  Duration of subject ’s participation in the study will be approximately 
[ADDRESS_374246] (including up to 4-week screening period)   
Number of Sub jects:  Approximately 33 subjects   
Study Population:  Subjects with newly diagnosed DME  (diagnosis within 6 months of 
screening ) that have received up to 2 prior injections of anti- VEGF 
therapy in the study eye.   
Randomization 
Criteria:   Subjects must meet the following criteria to be included in this study :   
Inclusion Criteria:  1) Male or female subjects, age ≥ 18 years of age  
2) Type 1 or 2 diabetes mellitus 
3) Ability and willingness to provide informed consent to participate in 
the study requirements and visits prior to any study procedure 
4) Vision at Screening visit: 
14 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374247]  2021 
 CONFIDENTI AL Page 15 of 74 a) Study Eye- BCVA 78 to 50 ETDRS letters, inclusive 
(approximate Snellen equivalent 20/32 to 20/100 )  
b) Non-study eye- BCVA 35 E TDRS letters or more (approximate 
Snellen equivalent of 20/200 or better)  
5) CST of study eye at Screening visit of ≥  325μm  using Heide lberg 
Spectralis® with center involving intraretinal fluid  (IRF)  
6) A decrease in vision in the s tudy eye determ ined by [CONTACT_305808]  
7) Initial DME diagnosis within 6 months  from s creening   
8) Up to 2 prior injections (0, 1 or 2) of anti -VEGF  in the study e ye  
• If a prior anti-VEGF has been administered to the study eye, in 
the judgemen
t of the Investigator, there must have been a 
meaningful CST response (e.g., ≥  10% reduction) and no adverse 
reaction  to anti -VEGF  (e.g., inflammation). 
9) A minimum [ADDRESS_374248] anti -VEGF 
IVT injection in the study eye and randomization on Day 1 
Exclusion Criteria:  Participants with any of the following conditions are ineligible:  
General Exclusion Criteria  
  
 
2) Any condition that, in the opi[INVESTIGATOR_871], could 
contraindicate the use of the investigational dru g or that might affect 
interpretation of the study results or that renders the subject at high 
risk for treatment complication s.   
3) Received an  investigational medicinal product within 60 days or 5 
half- lives prior to dosing with ADVM -022, whichever is longer  
4) Prior ocular gene therapy 
5) History of allergy to aflibercept, corticosteroid, or fluorescein dye or 
sodium fluorescein  used in angiography (mild allergy amenable to 
treatment is a llow
able) 
6) Pregnancy 
a) Women who ever intend to become pregnant 
b) Women who are currently or ever intend to breastfeed  
c) For women of childbearing potential (a woman is considered to 
be of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state (>12 continuous months of 
15 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
I 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374249]  2021 
 CONFIDEN TIAL  Page 16 of 74 amenorrhea with no identified cause other than menopause), and 
has not undergone surgical sterilization (removal of both ovaries 
and/or uterus). The definition of childbearing potential may be 
adapted for alignment with local guidelines or requirements ): 
i) May participate only if they have a negative pregnancy test at screening  
ii) Must agree to remain abstinent (refrain from heterosexual interco
urse) or use acceptable contraceptive measures that 
result in failure rate < 1% per year  
(1) Examples of acceptable contraceptive methods include bilateral tub
al ligation, male sterilization; ho rmonal 
contraceptives that inhibit ovulation, hormone- releasing 
intrauterine devices; and copper intrauterine devices.  
(2) Contraception methods that do not result in a failure rate of < 1% per year such as male or female condom with or without spermicide; and  cap, diaphragm, or sponge with 
spermicide are not acceptable. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calen dar, 
ovulation, symptothermal, or postovulation methods) and 
withdrawal are not acceptable methods of contraception.  
7) History or evidence of any of the following cardiovascular disease 
within 6 months of dosing: 
a) Severe cardiac disease (e.g., [LOCATION_001] Heart Association 
[NYHA] Fu
nctional Class III or IV) or clinical evidence of 
unstable angina 
b) Acute coronary syndrome, myocardial infarction or coronary artery reva
scularization  
c) Ventricular tachyarrhythmias requiring ongoing treatment, or uncontro
lled arrhythmia   
d) Uncontrolled hypertension defined as systolic blood pressure (SBP) >160 m
mHg or a diastolic blood pressure (DBP) >100 
mmHg, despi[INVESTIGATOR_305796]–lowering medication within the screening period. If BP -lowering medications are required, 
subject should be on a stable dose of the same medication continuously for 30 days prior to randomization. 
e) History of cerebrovascular accident or transient ischemic attack  
8) Any history of ongoing bleeding disorders.  The use of aspi[INVESTIGATOR_305797] (e.g., Factor Xa inhibitors) is not an exclusion.   
16 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374250]  2021 
 CONFIDENT IAL Page 17 of 74 9) HbA1C >10%; or history of diabetic ketoacidosis within 3 months 
prior to randomization; or subjects who, within the last 3 months, 
initiated intensive insulin treatment (a pump or multiple daily 
injection) or plan to do so in the next 3 months 
 
 
 
 
 
12) History o
f malignancy within the last 5 years except for the 
following ad
equately treated:  
a) Local basal cell or squamous cell carcinoma of the skin   
b) Carcinom
a in situ of the cervix or breast  
c) Papi[INVESTIGATOR_1396], noninvasive bladder cancer   
d) Prostate cancer Stage 1 and 2 for which observation is clinically indicated w
ith stable prostate -specific antigen (PS A) for 6 
months  
e) Any other cancer that has been in complete remission for at least 2 years or c
onsidered surgically cured 
13) Known to be positive for HIV or active viral hepatitis (unless document
ed cure after treatment for Hepatitis C )  
14) Known history of syphilis  
15) Known severe renal impairment, as indicated by [CONTACT_305809] <30 
mL/min (by [CONTACT_3158] -Gault calculation); need or anticipated need 
for hemodialysis during the study period 
16) Other significant laboratory abnormalities that the Investigator feels may compromise the subject’s safety  
17) Any febrile illness within 1 week prior to randomization. 
Ocular Exc
lusion Criteria (Study Eye) 
18) High -risk PDR  at time of s creening , defined as: any vitreous or 
preretinal hemorrhage, neovascularization elsewhere >1/[ADDRESS_374251] ETDRS 7- field on clinical 
examination, or neovascularization of disc > 1/3 -disc area on 
clinical examination  
17 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374252]  2021 
 CONFIDENT IAL Page 18 of 74 19) Any prior focal or grid laser photocoagulation or any prior PRP in 
the study eye  
 
 
  
 
 
  
 
 
 
23) History of retinal disease in the study eye other than diabetic 
retinopathy including age -related macular degeneration  (in either 
eye), retinal vein occlusion, retinal arter ial occlusion, pathologic 
myopia etc.)  
24) Any current or history of ocular disease other than DME that, coul d 
reduce
 the potential for visual improvement, confound assessment 
of the macula  or require medical or surgical intervention during the 
study (e.g. significant cataract, macular traction)  or any evidence of 
posterior subcapsular cataract    
25) History of cataract extraction  or YAG ca psulotomy  within 3 months 
before Day 1 
26) History of retinal detachment (with or without repair) in the study eye 
27) Histor
y of trabeculectomy or glaucoma shunt or minimall y invasive 
glaucoma surgery (MIGS)  
 
 
 
 
  
 
18 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Advernm Biotechno logies , Inc. ADVM-022 (AA V.7m8 -aflibercept) 
Protocol No. ADVM-022 -04 (Amendmen t 7.0) 
Adverum Biotechnologi es, Inc. 
Clinical Protocol No. ADVM-022-04 ADVM- 022 (AA V.7m8-aflibe1 ·cept) 
Amendment 7.0, [ADDRESS_374253] 2021 
Minimization of 
Bias: 
Method of 
Admini stration: Ocular Exclu sion Criteria (Fellow or Study Eye) 
36) Known histo1y of ocular HSV, VZV , or CMV including viral 
uveitis, retinitis or keratitis 
37) Evide nce of external ocular infect ion, including conjunctivitis, 
chalazion or significant blepha1 itis 
38) Histo1y of ocular toxop lasmosis 
Subjects will be randomized to one of [ADDRESS_374254], the physician and/or staff conducting 
outco me assessme nts, the central reading cente r and the sponsor. At the 
study site, only the site staff that prepares the study diug for 
administratio n and the physician administe1ing the study diug will be 
unmasked . See the IMP manual for additional details. 
An independent review of OCT images, fluorescein angiogra phy (FA) 
and fundus photogra phs, will be perfo1med at a central reading center to 
provide an objective assessment of these evaluations. 
Safety and disease activity assess ment w ill be perfo1 med by [CONTACT_305810] n. 
Unmasking of subjec t treatme nt assignments was planned to be 
rese1ved until the end of the study . Emerge ncy unmas king for all 
subjects has been required, as dete1mined by [CONTACT_305811], to preserve subject safety . The 
study in effect has become an open-label study, in which all prior 
masked roles will be able to continue study paiticipation in an 
unmasked manner. 
Both ADVM -022 and afliberce pt will be administe red via IVT 
injection . Aseptic techni que with povidone-iodine will be employed. 
Topi[INVESTIGATOR_199]/or subconjunctival anesthes ia will also be used. Post-
injectio n cai·e and medicatio n regimen w ill be given based as 
institutional standai·d of care. 
The sham ocular injection procedure will also be done under the same 
conditions but with an empty syiinge without a needle (using the blunt 
end) pressed against the eye to mimic an injection . 
CON FIDE NTIAL Page 19 of 74 
IND 0198 49 / Sequence No. 0018 CONFI DENTIAL 19 of74 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374255]  2021 
 CONFIDEN TIAL  Page 20 of 74 Safety Assessments:  The safety of ADVM -022 will be assessed through the collection of 
AEs, vital signs, physical examinations, ocular examinations, imaging , 
and laboratory evaluations.  
Statistical Methods 
and Data Analysis: No formal statistical testing is planned for the study. All safety and 
efficacy variables will be summarized descriptively by [CONTACT_2939]. 
Mean, standard deviation (SD), median and range will be provided for continuous variables; and frequency counts and percentages will be provided for categorical variables.  Kaplan -Meier survival analysis will 
be utilized to derive median time to the first occurrence  
of DME disease 
worsening. All rescue aflibercept injections received by [CONTACT_305812].  Mean cumulative function (MCF) curve over time 
will be plotted for the mean cumulative number of injections.  Mixed -
effect models for repeated measures (MMRM) will be employed to explore the t
reatment effect on the change over time in BCVA and CST.  
The treatment effect on DRSS changes over time will be explored using generalized mixed models for categorical outcomes.  Interim analysis is 
planned after all subjects have been followed [ADDRESS_374256] has become an open -label study .   
 
20 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374257] OF ABBREVIATIONS  
Abbreviation or Term  Definition/Explanation  
AAV  Adeno -Associated Virus  
AE Adverse Event  
AMD  Age-Related Macular Degeneration  
BCVA  Best Corrected Visual Acuity  
BID Two times a day  
cDNA  Complementary DNA  
CBC  Complete blood count  
CFR  Code of Federal Regulations  
CIOMS  Council of International Organizations of Medical Sciences  
CMV  Cytomegalovirus  
CNV  Choroidal Neovascularization  
CRF  Case Report Form  
CrCl  Creati nine Clearance  
CRO  Clinical Research Organization  
CST Central Subfield Thickness  
CTA  Clinical Trial Agreement  
DBP  Diastolic Blood Pressure  
DM Diabetes Mellitus  
DMC  Data Monitoring Committee  
DME  Diabetic Macular Edema  
DR Diabetic Re tinopathy  
DRSS  Diabetic Retinopathy Severity Sc ale 
eCRF  Electronic Case Report Form  
ECG  Electrocardiogram  
EDC  Electronic data capture  
  
  
EOS  End of Study  
21 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
--
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374258]  2021 
 CONFIDENTI AL Page 22 of 74 Abbreviation or Term  Definition/Explanation  
ETDRS  Early Treatment of Diabetic Retinopathy Study  
FA Fluorescein Angiography  
FDA  US Food and Drug Administration  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HED  Human equivalent dose  
HIPAA Health Insurance Portability and Accountability Act of [ADDRESS_374259]  model for repeated measures  
22 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
-1-• 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374260]  2021 
 CONFIDENTI AL Page 23 of 74 Abbreviation or Term  Definition/Explanation  
  
nAMD  Neovascular (wet) Age -Related Macular Degeneration  
NSAID  Nonsteroidal anti -inflammatory drug  
NHP  Nonhuman Primate  
NYHA  [LOCATION_001] Heart Association  
OCT  Optical Coherence Tomography  
OCT -A Optical Coherence Tomo graphy Angiography  
OTC  Over the counter  
OU Oculus Uterque  (both eyes)  
PASS  Power and Sample Size  (a propri etary software)  
PDR  Proliferative Diabetic Retinopathy  
PE Physical Examination  
PRP Pan Retinal Photocoagulation  
PSA Prostate -specific antigen  
PT Preferred term  
Q2hr Every [ADDRESS_374261]  Spectral Domain Optical Coherence Tomography  
SE Study Eye  
23 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
-I-
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374262]  2021 
 CONFIDEN TIAL  Page 24 of 74 Abbreviation or Term  Definition/Explanation  
Sf9 Clonal isolate of Spodoptera frugiperda  Sf21 commonly used in 
insect cells culture for recombinant protein production using 
baculovirus 
sFLT -1  Soluble FLT -1 Receptor / Soluble VEGFR1 Receptor  
SOC  System Organ Class  
sVEGFR  Soluble Vascular Endothelial Growth Factor Receptor  
TID Three times a day  
UBM  Ultrasound Biomicroscopy  
VA Visual Acuity  
VEGF  Vascular Endothelial Growth Factor  
VEGFR1  Vascular Endothelial Growth Factor Receptor 1  
VEGFR2  Vascular Endothelial Growth Factor Receptor 2  
VZV  Varicella -zoster virus  
YAG  Yttrium Aluminum Garnet   
24 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374263]  2021 
 CONFIDEN TIAL  Page 25 of 74 3.0 BACKGROUND  
3.1 Introduction  
Diabetic Retinopathy ( DR) is a major complication of diabetes mellitus (DM) and is a leading 
cause of visual loss in the working age population (Wang 2018) .  Diabetic Macular Edema 
(DME ) is a complication of DR that affects central vision and can lead to a decline in vision 
ranging from slight visual blurring to blindness, substantially affecting independence and quality 
of life  (Varma 2014) . Anti-v ascular endothelial growth f actor  (anti -VEGF ) agents such as 
aflibercept ( Eylea®), approved by [CONTACT_2165] (FDA), have demonstrated 
effectiveness at improving and maintaining vision in patients with DR and DME.  However, 
patients with DR and DME can struggle to adhere to treatment regimens with Eylea that call for 
monthly or bimonthly intravitreal (IVT) injections often leading to suboptimal outcomes in the 
real world.  This may be because diabetic patients are subject to significant lapses in follow -up 
because of illness, fi nancial hardship or noncompliance. In patients treated with currently 
available anti -VEGF therapy alone, unintentional treatment interruptions can result in blinding 
complications including vitreous hemorrhage and tractional retinal detachment (Wubben 2019) .  
There is, therefore, an unmet need for a long- acting anti -VEGF agent that can reduce the risks 
associated with lapses in follow -up. 
Gene -based delivery of anti-VEGF proteins has the potential to provide sustained intraocular 
anti-VEGF protein expression following a single administration, addressing this unmet medical 
need .  ADVM -[ADDRESS_374264] that uses an adeno- associated viral vector capsid 
(AAV.7m8) encoding DNA for aflibercept  and is administered as a single IVT  injection.  
ADVM -[ADDRESS_374265] (ADVM -022) 
The investigational medicinal product (IMP), ADVM -022 ( AAV.7m8 -aflibercept), is a 
recombinant, replication- deficient adeno -associated viral (rAAV) vector containing the 
AAV.7m8 protein capsid derived by [INVESTIGATOR_2993]-vivo directed evolution on the AAV2 capsid 
(Dalkara 2013) .  ADVM -022 carries an expression cassette of a codon -optimized version of the 
aflibercept  complementary DNA  (cDNA) under the control of a ubiquitous promoter.  ADVM -
[ADDRESS_374266] 
for anti- VEGF drugs currently administered to patients.  
25 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374267]  2021 
 CONFIDEN TIAL  Page 26 of 74 3.3 Preclinical Summary for ADVM-022 
Results from nonhuman primate (NHP) preclinical pharmacology studies of ADVM -022 
conduc
ted in a clinically relevant animal model of ocular neovascularization, laser -induced 
choroidal neovascularization ( CNV), demonstrated the robust pharmacologic effects of 
ADVM -022 (Grishanin  2019) .  A single IVT injection of ADVM -022 administered 2 months or 
13 months prior to laser photocoagulation reduced Grade IV  lesion development to the same 
extent as a 1.2 mg IVT  bolus of aflibercept recombinant protein (a current standard of care for 
nAMD and DR including DME ) administered at the time of lesioning.  The effect of ADVM -022 
treatment on Grade IV CNV lesion incidence (as measured by [CONTACT_62872]) correlated with smaller size 
of fibrovascular CNV complexes (as measured by [CONTACT_66309] -OCT).  Notably, the effec ts on CNV 
development were identical whether the lesions were induced [ADDRESS_374268] time point assessed (Johnston 2013) .  
ADVM -022 administration was well -tolerated, showing transient intraocular inflammation that 
generally resolved over time.  The preclinical pharmacology studies provide a strong demonstration of the potential efficacy of IVT- delivered ADVM -022. 
3.4 Other Clinical Studies of ADVM -022  
Clini
cal Protocol No. ADVM-022-01 (also referred to as the OPTIC stu dy, ClinicalTr ials.gov 
Identifier: [STUDY_ID_REMOVED]) is a Phase 1, open- label , multi -center study to evaluate the safety and 
tolerability of a single IVT injection of ADVM -[ADDRESS_374269] corrected visual acuity (BCVA), 
central subfield thickness (CST), macular volume, the need for rescue therapy, and presence of subretinal or intraretinal fluid.  
To be eligible for the study, subjects needed to be older than [ADDRESS_374270] had prior or current evi
dence of active subfoveal CNV secondary to Age -Related Macular Degeneration  
(AMD), have received a minimum of [ADDRESS_374271] vision in the study eye between 78 to 25 Early Treatment of Diabetic Retinopathy Study (ETDRS ) letters, have vision in the non-study eye of ≥  [ADDRESS_374272] by 30% or a 
reduction from screening in CST by 20% or normalization of CST with no wet AMD activity.  Eligible subjects enrolled in the first t wo cohorts (Cohorts 1 and 2) received a dose of ADVM-
022 at 6  × 10
11 vg/eye and 2 × 1011 vg/eye, respectively , with a prophylactic oral prednisone 
regimen .  Cohorts 3 and 4 subjects received a dose of ADVM -022 at 2 × 1011 vg/eye and 6×1011 
vg/eye, respecti vely, with a prophylactic topi[INVESTIGATOR_305798] . 
26 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374273] study visit (104 weeks), with similar ongoing assessments, 
Clinical Protocol No. ADVM-022- 07 [OPTIC -EXT] ( ClinicalTrials.gov: NCT04 645212), 
initiated in November 2020.  
 
 
The OPT
IC study population consisted of patients who previously required frequent injections to 
maintain vision
. The mean years since diagnosis per cohort were 4.5 years, 4.1 years, 3.3 years, 
and 3.2 years for Cohorts 1- 4 respectively . The mean number of anti- VEGF injections in the 12 
months prior to receiving ADVM -022 were 9.2, 9.2, 9.1, and 7.1 in Cohorts 1- 4 respectively .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374274]  2021 
 CONFIDENT IAL Page 28 of 74  
 
 
 
 
 
 
 
 
 
 
28 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374275]  2021 
 CONFIDENT IAL Page 29 of 74  
29 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374276]  2021 
 CONFIDENT IAL Page 30 of 74  
 
 
30 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.  ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374277] is formulated in a buffer composed of 180 m M NaCl, 5  mM Na 2HPO 4, 
5 mM NaH 2PO 4, and 0.001% Poloxamer [ADDRESS_374278] is 
supplied as a sterile -filtered , frozen suspension in a sterile,  ready -to-use 0.5  mL Crystal Zenith® 
vial which contains approximately 0.[ADDRESS_374279] .  The vial is 
stoppered with a sterile, ready -to-use stopper made of chlorobutyl and sealed with a sterile 
aluminum seal.   The filled vials are placed in an outer carton and  stored at ≤ -60°C. 
3.[ADDRESS_374280] been studied using the same doses from their nAMD  studies in their DME studies.   These 
studies subsequently demonstrated that those treatments were also safe and efficacious in DME. 
 
      
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
31 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374281]  2021 
 CONFIDENT IAL Page 32 of 74  
 
 
  
 
 
 
 
 
 
 
4.0 CLINICAL
 STUDY OBJECTIVES AND ENDPOINTS  
4.1 Objectiv
es 
4.1.1 Primary O
bje ctive  
• To assess the durability of a single IVT injection of ADVM -022  
4.1.2 Secondary Ob jectives 
Secondary Objectives : 
• To assess the safe
ty and tolerability of ADVM-022 
• To evaluat
e the effect of ADVM-022 on macular edema  
• To evaluat
e the effect of ADVM-[ADDRESS_374282] Corrected Visual Acuity (BCVA)  
• To evaluat
e the effect of ADVM-022 on Diabetic Retinopathy Severity Scale (DRSS) score 
• To assess the need
 for rescue aflibercept (2  mg IVT)   
• To
 assess the effect of a preceding dose of aflibercept (2  mg IVT) pri or to ADVM -022 
administration  
32 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374283]  2021 
 CONFIDEN TIAL  Page 33 of 74 • To evaluate the effect of ADVM-022 on development of vision threatening complications 
(including anterior segment neovascularization, vitreous hemorrhage, or tractional retinal detachment)  
4.2 Endpoints  
4.2.1 Primar
y E ndpoints  
Time to worsening of DME disease activity in the study eye, as defined by [CONTACT_305813]: 
• An
 increase in CST > [ADDRESS_374284] 
measurements recorded at Day 1 or Week 4  
• A loss of > 5 letters in BCVA due to worsening DME disease activity  compare d to the higher 
of the two BCVA measurements recorded  at Day  1 or Week 4  
4.2.2 Secondary  Endpoi nts   
Unless specified otherwise, the secondary endpoints are based on outcome measures for the 
study eye. 
• I
ncidence and severity  of ocula r and non-ocular adverse events (AEs)  
• Change from Baseline in  central su bfield thickness (CST)  and macular volume over time  
through Week 96 
• Change from Baseline in BCVA over time through Wee k 96   
• Frequency of r escue afliber cept (2  mg IVT) in the study eye over time during the study 
• Incidence of  2-step and 3 -step improvement in DRSS score  over time through Week  96  
• Incidence of  2-step and 3 -step worsening in DRSS score over time through Week  96  
• Occur rence  of visi on threatening complication (anterior segment neovascularization, vitreous 
hemorrhage, or any other high- risk proliferative DR, or tractional retinal detachment) over 
time through Week 96 
• Incidence of CST <300 μm over ti me through Week 96 
• Incidence of clinically significant findings via physical examinations, ocular examinations, 
imaging, a
nd laboratory evaluation 
5.0 CLINICAL INVESTIGATION PLAN  
5.1 Study Des
ign 
This is a 
multi -center, r andomized, double-masked, controlled, parallel-group study to evaluate 
the efficacy, safety and tolerability of a single IVT injection of ADVM -022.  Two doses of 
ADVM -022 will be investigated.  
33 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374285] received up to 2 
prior injections of anti- VEGF therapy are eligible for enrollment.  
Approximately 33 eligible subjects will be random ized to one of 5 arms.  Arm 1 (n=6) will 
receive ADVM -022 6 × 1011 vg/eye with a preceding aflibercept dose. Arm 2 ( n=6) will receive 
ADVM -022 6 × 1011 vg/eye of without a preceding aflibercept dose. Arm 3 (n=6) will receive 
ADVM -022 2 × 1011 vg/eye with a preceding aflibercept dose. Arm 4 (n=6) will receive 
ADVM -022 2 × 1011 vg/eye of without a preceding aflibercept dose. Arm 5 (n=9) will receive 
aflibercept only (active control).   To maintain masking of the treatment assignment, subjects 
assigned to the arms with no preceding aflibercept on Day [ADDRESS_374286] will be selected as the study eye.  If both eyes are eligible, the eye with the worse BCVA will be the study eye.    
Subjects wi ll be randomized to the following treatment arms in  Table  3. 
Ta
ble 3: Study Arms  
Arm N Day 1  
IVT Aflibercept or Sham  Day 8  
ADVM -022 Dose  (vg/eye)  
1 6 Aflibercept  6 × 1011 
2 6 Sham  6 × 1011 
3 6 Aflibercept  2 × 1011 
4 6 Sham  2 × [ADDRESS_374287] become an open -label study, in which all prior 
masked roles will be able to continue study participation in an unmasked manner. 
5.1.1 : 
 
 
    
34 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374288]  2021 
 CONFIDENT IAL Page 35 of 74 5.1.2 Rescue Treatment:  
Starting at Week 8, subjects w ill receive rescue aflibercept (2 mg IVT ) if they meet any of the 
following:  
• Increase in CST > [ADDRESS_374289] 
measurements recorded at Day 1 or Week 4  
• Loss of > 5 letters in BCVA due to worsening DME disease activity compared to  the higher 
of the two BCVA measurements recorded at Day  1 or Week 4  
After initial rescue treatment administration,  
 Primary
 Investigator.  
Only intravitreal aflibercept injection (Eylea) is to be used for any rescue treatment unless prior 
approval by [CONTACT_305814].  
Aflibercept should not be injected in eyes with active inflammation. A minimum of 21 days is required bet
ween rescue aflibercept injections. 
5.1.3 Data Monito ring Committee  (DMC):  
An independent DMC will monitor safety and study conduct on an ongoing basis. Members of the DMC will be
 independent from the Sponsor and will follow a charter that outlines the DMC's 
roles and responsibilities. The DMC will meet every 3 -6 months (frequency adjustable as 
required) to evaluate unmasked ocular and non-ocular safety events, with emphasis on the evaluation of the rate of ocular inflammation, increased IOP, endophthalmitis, and clinically significant decreases in BCVA. The DMC will also meet on an ad hoc basis if stoppi[INVESTIGATOR_305799]. The DMC may recommend stoppi[INVESTIGATOR_78742]. After reviewing the data, the DMC will provide a recommendation to the Sponsor as described in the DMC Charter. Any outcomes of these data reviews that affect study conduct will be communi cated in a timely manner to the investigators for notification of their respective 
Institutional Review Boards  (IRBs) . 
5.1.4 Stoppi[INVESTIGATOR_1869]
 : 
Enrollment will be suspended if any of the following sight threatening events occur:  
• A decrease of ≥ 30 letters in BCVA in the study eye compared with the prior visit  
• A surgical intervention (i.e., conventional surgery, vitrectomy) to prevent permanent loss of 
sight.  
• Severe intraocular inflammation (i.e., endophthalmitis, 4+ anterior chamber cell/flare, or 4+ vitreous cell s)
  
In addition, enrollment will be suspended if any serious adverse event potentially related to 
ADVM -022 occurs.  
35 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374290]  2021 
 CONFIDEN TIAL  Page 36 of 74 Any event that meets any of the above safety stoppi[INVESTIGATOR_305800] a recommendation to the Sponsor. 
The regulatory authorities and the Investigators, and each site’s IRB and other appropriate 
institution
al regulatory bodies will be promptly notified if a decis ion to suspend enrollment is 
made.  
If study enrollment is suspended, all subjects who have already been treated will remain in the study and will
 continue to be monitored through their completion or withdrawal from the study    
5.[ADDRESS_374291] ’s participa tion in the study will be approximately [ADDRESS_374292] 
(including up to 4- week screening period) .  
5.3 Study Population  
Subjects
 with newly diagnosed DME (diagnosis within 6 months of screening) that have 
received up to
 [ADDRESS_374293]’s treatment assignmen t throughout the study.  There must be a minimum of 
two physicians per site to fulfill the masking requirements of the study.  A masked and unmasked investigator are required to be present for the Day [ADDRESS_374294] has 
become an open -la 
bel study, in which all prior masked roles will be able to  continue study 
participation in an unmasked manner. 
36 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374295]  2021 
 CONFIDEN TIAL  Page 37 of 74 5.5.1 Masked Roles  
If qualified, the study site personnel with masked role can take on any other masked role tasks 
except for
 tasks performed by [CONTACT_305815]. The designated roles for masked study site 
personnel include : 
• Assessor physician (typi[INVESTIGATOR_305801]) who evaluates all pre -treatment 
assessment as well as all safety and disease activity assessment at all visits 
• Photographer(s) and OCT technician(s) 
• Study Coordi
nator(s) who have any interaction with study subjects including assessments 
• BCVA e
xaminer who will be masked to both the assigned treatment and the location (OD, 
OS) of the
 study eye.  The BCVA examiner will have no access to subjects’ medical record 
or the BCVA score  from subjects’ previous visits and may have access only to a subject’s 
refraction data from previous visits.  The BCVA examiner is not allowed to perform any other task involving direct subject care. 
Additionally, study CRO staff (except those who are responsible for drug accountability or randomizat
ion), sponsor clinical study team , the Central Reading Center and the Central Lab 
personnel will be masked.  
5.5.2 Unmasked R oles 
Every effort should be made to limit the number of unmasked study personnel to ensure the integrit
y of this masked study.  There should be no more than six unmasked personnel at a study 
site at one time.   In certain circumstances, the total number of unmasked personnel might be 
increased after discussion with and approval by [CONTACT_1034].  An y other study personnel not 
listed below will be in the masked roles.  
• Treatment administrator: a retina specialist or a qualified ophthalmologist who is designated to perfor
m the study treatment administration at Day 1 and Day 8.  He/she can conduct  
assess ment prior to randomization visit as well as the post- treatment procedure (i.e. , IOP, 
indirect ophthalmic examination and slit lamp) including the optional aqueous humor sample collection .  The person in this role will treat any adverse events that occur d uring or shortly 
after the study treatment administration; however, will not evaluate the causality of adverse events which is the responsibility of the masked assessor physician.  
• Either the assessor physician or the treatment administrator can administer rescue aflibercept (2 mg IVT).
 
• Coordinator(s) and Pharmacist: A designated personnel who receives IMP and prepares the study trea
tment at Day [ADDRESS_374296] who performs study treatment related tasks per the Delegation of Authority Log. 
37 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374297]  is necessary fo r a medical emergency ( e.g., in the case of a 
serious adverse event for which patient management might be affected by [CONTACT_123514]) the investigator should contact [CONTACT_295712].  
Emergency unmasking for all subject s has been required, as determined by [CONTACT_305816], to preserve subject safety. The study has in effect become an open -label study, in which all prior masked roles will be able to continue study 
participation in an unmasked manner.  The unmasking process and sharing of subject treatment 
assignments will be communicated by [CONTACT_305817].     
5.[ADDRESS_374298] of care.   
5.10   
 
 
 
38 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374299] 
the following minimum information:  
• Subjects screening number  
• Randomizat
ion Status  
• Screen Fail r
eason (if applicable)  
40 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374300]  2021 
 CONFIDENTI AL Page 41 of 74 6.3 Inclusion Criteria  
1) Male or female subjects, age ≥ 18 years of age  
2) Type 1 or 2 diabetes mellitus 
3) Ability and willingness to provide informed consent to participate in the study requirements 
and visits pri
or to any study procedure 
4) Vision at Screening visit: 
a) Study Eye- BCVA [ADDRESS_374301] S letters, inclusive (approximate Snellen equivalent 
20/32 to 20/100)  
b) Non-study eye- BCVA 35 ET DRS letters or more (approximate Snellen equivalent of 
20/200 or better) 
5) CST of study eye at Screening visit of ≥  325μm using He idelberg Spectralis® with center-
involving IRF (center 1 mm)  
6) A decrease in vision in the study eye determined by [CONTACT_305818]  
7) Initial DME 
diagnosis within 6 months from screening  
8) Up to 2 prior injections (0,  1, or 2) of anti-V EGF in the study eye 
a) If a prior anti-VEGF has been administered to the study eye, in the judgement of the Investigato
r, there must have been a meaningful CST response (e.g. ≥  10% reduction) and 
no adverse reaction  to anti- VEGF  (e.g. inflammation) 
9) A minimum [ADDRESS_374302] anti -VEGF injection in the study eye 
and randomization on Day 1 
6.4 Exclusion Criteria   
Participan
ts with any of the following conditions are ineligible:  
6.4.1 General Exclusi on Criteria  
  
2) Any condition tha
t, in the opi[INVESTIGATOR_871], could contraindicate the use of the 
investigati
onal drug, ADVM -022, or that might affect interpretation of the study results or 
that renders the patient at high risk for treatment complications    
3) Received an investigational medicinal product within 60 days or 5 half-lives prior to dosing with ADVM -022, which 
ever is longer  
4) Prior ocular gene therapy 
5) H
istory of allergy to aflibercept, corticosteroid, or fluorescein dye or sodium fluorescein  used 
in angiog
raph
y (mild allergy amenable to treatment is allowable)  
41 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
I 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374303]  2021 
 CONFIDEN TIAL  Page 42 of 74 6) Pregnancy 
a) Women who ever intend to become pregnant  
b) Women who are currently or ever intend to breastfeed  
c) For women of childbearing potential (a woman is considered to be of childbearing 
potential
 if she is postmenarcheal, has not reached a postmenopausal state (>12 continuous 
months of amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of both ovaries and/or uterus) . The definition of 
childbearing potential may be adapted for alignment with local guidelines or requirements): 
i) May participate only if they have a negative pre gnancy tes
 t at screening  
ii) Must agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable c
ontraceptive measures that result in failure rate <1% per year :  
(1) Examples of acceptable contraceptive methods include bilateral tubal ligatio n, 
male steril
ization; hormonal contraceptives that inhibit ovulation, hormone -
releasing intrauterine devices; and copper intrauterine devices   
(2) Contraception methods that do not result in a failure rate of < 1% per year such as male or fema
le condom with o r without spermicide; and cap, diaphragm, or 
sponge with spermicide are not acceptable.  The reliability of sexual abstinence 
should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.    
7) History or evidence of any of the following cardiovascular disease within 6 months of dosing: 
a) Sever
e cardiac disease (e.g., [LOCATION_001] Heart Association [NYHA] Functional Class III or 
IV) or cl
inical evidence of unstable angina    
b) Acute coronary syndrome, myocardial infarction or coronary artery revascularization    
c) Ventricular tachyarrhythmias requiring ongoing treatment, or uncontrolled arrhythmia    
d) Uncontrolled hypertension defined as systolic blood pressure (SBP) >160 mmHg or a 
diastolic b
lood pressure (DBP) >100 mmHg, despi[INVESTIGATOR_305796]–lowering medication 
within the screening period. If BP -lowering medications are required, subject should be on 
a stable dose of the same medication continuously for 30 days prior to randomization.  History of cerebrovascular accident or transient ischemic attack     
8) Any history of ongoing bleeding disorders.  The use of aspi[INVESTIGATOR_305802] (e.g., Factor Xa
 inhibitors) is not an exclusion.     
42 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Advernm Biotechnolog ies, Inc. ADVM- 022 (AA V.7m8-afl ibercept) 
Protocol No. ADVM- 022-04 ( Amendmen t 7.0) 
Adver um Biotechnologies, Inc. 
Clinical Prot ocol No. ADVM-022-04 ADVM-022 (AA V.7m8-a flibe1·cept) 
Ame ndme nt 7.0, [ADDRESS_374304] 2021 
9) HbAlC >10%; or histo1y of diabe tic ketoacidosis within 3 month s p1ior to randomiz ation; or 
subjects who, within the last 3 months, initiated intensive insulin treatment (a pump or 
multip le daily inject ion) or plan to do so in the next 3 months. 
12) Histo1 y of malignanc y within the last 5 years excep t for the following adequa tely trea ted: 
a) Local basal cell or squamou s cell carcinoma of the skin 
b) Carcinom a in situ of the ce1vix or breast 
c) Papi[INVESTIGATOR_24124] y, noninv asive bladder cancer 
d) Prostate cancer Stage 1 and 2 for which obse1vation is clinically i ndicated with stable 
prostate-specific antigen (PSA) for 6 months 
e) Any other cancer that has been in complete remission for at least 2 years or considered 
surgically cured 
13) Known to be positive for HIV or active viral hepatitis (unless document ed cure after 
treatment for Hepatitis C) 
14) Known histo1y of syphili s 
15) Known severe renal impai1ment , as indic ated by [CONTACT_305809] <30 m L/min (by [CONTACT_3158]-
Gault calcula tion); need or ant icipated need for hemod ialysis during the study period 
16) Other significant laborat o1 y a bno1m alities that the Investigator feels may comprom ise the 
subject's safety 
17) Any feb1ile illness within 1 week prior to randomiz ation 
6.4.2 Ocular Exclusion Criteria (Study Eye) 
18) High-risk PDR at time of screening , defined as: any vitr eous or preretina l hemoITh age, 
neov asculai·ization elsewhere> 1/2-disc ai· ea within an area equivalent to sta ndard ETDRS 7-
field on clinical examination, or neov asculai· ization of disc > 1/3 -disc ai· ea on clinical 
examination 
19) Any prior focal or giid laser photocoagulation or any prior P RP in the study eye 
CONF IDENTIAL Page 43 of74 
IND 019849 / S equence No. 0018 CONFIDENTIAL 43 of74 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374305]  2021 
 CONFIDENT IAL Page 44 of 74  
 
 
 
23) History o
f retinal disease in the study eye other than diabetic retinopathy in cluding age-
re
lated macular degeneration (in either eye), retinal vein occlusion, retinal arterial occlusion, 
pathologic myopia , etc.  
24) Any current or history of ocular disease other than DME that, could reduce the potential for 
visual imp
rovement, confound assessment of the macula or require medical or surgical 
intervention during the study (e.g. significant cataract, macular traction) or any evidence of posterior subcapsular cataract  
25) History of cataract extraction or YAG capsulotomy within 3 months before Day 1 
26) History of retinal detachment (with or without repair) in the study eye  
27) History of trabeculectomy or glaucoma shunt or minimally invasive glaucoma surgery (MIGS)  
 
 
 
 
 
 
 
 
6.4.3 Ocular
 Ex
clu sion Criteria (Fellow or Study Eye)  
 
 
 
36) Known hist
ory of ocular HSV, VZV, or CMV including viral uveitis, retinitis or keratitis  
37) Evidence of external ocular infection, including conjunctivitis, chalazion or significant blephariti
s 
38) History of ocular toxoplasmosi s 
44 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374306]’s disease status and complete study assessment as specified by [CONTACT_990].   Any missing 
assessment will be recorded as the protocol deviation.  
A subject may discontinue the study for the following reasons: 
• Withdrawal of consent by t he subject  
• Lost to follow -up 
• Investi
gator ’s decision ( such as chronic noncompliance, adverse event(s) that put the safety of 
the subject at risk, significant protocol deviation, or best interest of the subject)  
• Study termination by [CONTACT_1034] 
•
 Death   
Subjects w
ho withdraw prior to receiving the study treatment (ADVM -022 IVT or Sham  ocular 
injection) on Day 8 after randomization will not be replaced directly.  However, the treatment 
allocation will be adjusted accordingly for subsequently enrolled subjects to achieve a target of 6 treated subjects/arm for the [ADDRESS_374307] in -person clinic visit s (e.g., in 
the case of a pandemic) , certain  safety assessments including medical history and concomitant 
medi cation  information  can be collected  via phone calls. The contact [CONTACT_305819]’s source document and the CRF should be updated accordingly. Additional ocular 
examination and imaging assessments should be captured in the presence of active intraocular 
inflammation and/or significant vision loss (greater than or equal to 15 letters loss  from 
Baseline ), refer to the management of i  (Section  5.11) and schedule of 
assessments ( Se
ction 18.1 and Section 18.2) . Additional assessment requirements may be 
reduced  based on s
everity and location of the inflammation on any subsequent follow-up visits. 
The procedure descriptions are as follows:    
45 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374308]’s willingness to participat e in the st udy must be obtained 
before performing any study- specific screening tests, evaluations, or procedures.  Subjects will 
be provided with an IRB-approved informed con sent form (ICF) detailing the IMP , study 
assessments, and study procedures.  Prior to being asked to sign the ICF, subjects will be given 
time to review the study information and ask questions. Acceptable remote methods of consent include mailing, emailing , and faxing of consent documents and telephone or video contact. 
7.[ADDRESS_374309] meets 
the inclusio
n/exclusion criteria prior to randomization on Day 1 ( Section 6.3 and Section 6.4).  In 
addition to the
 Investigator, the Central Reading Center will review imaging as part of eligibility 
assessment.  
7.3 Medical History, Ophthalmic History, and Demographics 
The subjec
t’s relevant medical and ophthalmic history will be collected and recorded.  The 
medical  hi
story collection period is defined as disease hist ory up until screening .  Concurrent 
medical signs and symptoms must be documented to establish baseline severities.  A disease history, including the date of initial diagnosis, prior treatments, dates administered, and responses will be recorded.  
7.4 General P hysical E
 xamination and Vital Signs  
The general physical examination (PE)  will be conduct ed at screening and End  of Study 
(EOS )/or Early Termination visit.  It  consist s of body system examination  for general 
appearance, neurologic, HEENT  (head, eyes, ears, nose, and throat), neck, cardiovascular, 
respi[INVESTIGATOR_696] , abdomen, extremities, skin , and weight .  Height will be measured at screening  only.  
At the EOS/ or Early Termination visit, the physical examination will assess if any changes in the 
subject’s physical condition have occurred since the Screening examination. A targeted physical exam ination  should be conducted as needed for the evaluation of AEs.   
Vital signs will consist of blood pressure, pulse rate,  body tempera
 ture, and respi[INVESTIGATOR_697].  
Systol ic and diastolic blood pressure and pulse rate will be measured after subjects have been at 
rest (seated) for at least 5 minutes.  
7.5 ECG Evaluation 
A 12 -lead El
ectrocardiogram ( ECG) will be  taken for each subject at Screening and EOS/or 
Early Termination Visit.  The Investigator will assess whether the ECG is normal, abnormal and not clinica 
lly significant, or abnormal AND clinically significant.   
46 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374310]  2021 
 CONFIDENTI AL Page 47 of 74 7.6 Laboratory Tests  
Clinical L aboratory , Vector Expr ession and Immune Response tests will be performed  centrally 
as specified in the Schedule of Assessments. The procedures for sample collection , process and 
shipment are described in the Study Laboratory Manual .  
7.6.1 Clinical Labor atory Tests  
The following Clinical Laboratory T ests will be conduc ted for the study:  
• Chemistry  
• CBC  
• HbA1C  
• Urina
lysis 
• S
erum or u rine
 Pregna ncy Testing ( females of child -bearing potential) 
• HLA-B27 genotypi[INVESTIGATOR_007]   
A detailed l
isting of clinical laboratory tests is outlined within the Study Laboratory Manual. 
Laboratory re
ports will be made available to the Investigator in a timely manner to ensure 
appropriate clinical review.   
7.6.2  
   
  
  
  
  
  
 
  
  
   
7.7 Full Ophth
almic Examination  
The assess
ment will include an ophthalmologic exam, Intraocular Pressure ( IOP), and indirec t 
ophthalmoscopy.   
47 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
I 
I 
I I 
I 
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374311] of an external examination of the eye and adnexa, 
routine screening for eyelid/pupil responsiveness (including but not limited to blepharoptosis, abnormal pupil shape, unequal pupi[INVESTIGATOR_8324], abnormal reaction to light, and afferent pupi[INVESTIGATOR_130783]), and slit-lamp examination (eyelids, conjunctiva, cornea, lens, iris, anterior chamber).  The slit-lamp examination will examine the anterior ocular structures and will be used for grading any findings.  If any finding is noted during the slit- lamp examination, at any visit, the severity will 
be graded by [CONTACT_305820].  
The IOP measurements will be performed using a Goldmann applanation tonometer or Tono-pen™, as specifi
ed in the Schedule of Assessments. The same method of IOP measurement must 
be used throughout the study for each individual subject .  IOP measurements will be performed 
prior to any IVT injection and prior to dilating eyes , using the same method throughout the 
study.  Every effort should be made to have IOP measurements performed at approximately the same time of day and using the same type of instrument for a given subject throughout the study, whenever possible.  Day [ADDRESS_374312]-injection (30 
minutes after injection) IOP measure ments. Study eye post injection IOP measurement is also 
required following any rescue aflibercept  injection.   Any post injection IOP measurements of the 
fellow eye are optional. 
The dilated indirect ophthalmoscopy examination will include an evaluation of posterior segment abnormaliti
es of the vitreous, optic nerve, peripheral retina, and retinal vasculature.  If any 
finding is noted during the ophthalmoscopy, at any visit, the severity will be graded by [CONTACT_305820].  Day [ADDRESS_374313]
ion and BCVA will be measured by a trained and certified visual acuity examiner(s) at 
the study site
s.  
Visual acuity measurements will be measured at a starting distance of [ADDRESS_374314] be certified prior to any visual acuity  examinations.  The full 
refraction and VA  procedure will be provided in the . 
48 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374315] (Retinal and 
Optional Anterior Segment Imaging ) 
SD-OCT is an interferometric technique that provides depth -resolved tissue structure information 
encoded in the magnitude and delay of the back- scattered light by [CONTACT_305821].  The s ame machine should be used for al l study visits.  Anterior 
segment images are optional if a site does not have the capability to take images of the anterior 
segment.  
If a subject received anti-VEGF inject ions at visits prior to study randomization, OCTs from 
those visits should be collected  and delivered to the central reading center .   
7.9.2 Optional Optical Coherence Tomography Angiography (OCT- A) 
OCT -A is an imaging technology that provides volumetric, three- dimensiona l maps of the retina 
and choroid as well as information on blood flow. This procedure is optional and will only be 
utilized at sites with OCT -A instruments.  There are two types of OC T-A, swept -source and 
spectral -domain.  Swept-source imaging should be used where available. If a swept-source 
instrument is not available and a spectral- domain instrument is available, then the spectral 
domain instrument should be used.  
7.9.3 Ultra -wide Field  Fundus Photography  and Iris Photography  
A standardized procedure for the collection of ultra -wide field fundus  digital photographic 
images of the retina, optic disc, and macula will be followed. In addition, photographs of the iris 
will be taken  prior to d ilation .  
7.9.4 Ultra -wide Fiel d Fluorescein Angiography  
A standardized procedure for examining the retinal circulation and vessel permeability using a 
dye-tracing 
method will be followed.  This involves injection of sodium fluorescein into the 
systemic circulat ion, after which an angiogram is obtained by [CONTACT_305822] a wavelength of 490 nm.  
49 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374316]  2021 
 CONFIDENT IAL Page 50 of 74 7.9.5 Optional Ultrasound Biomicroscopy (UBM) 
Ultrasound Biomicroscopy (UBM) is a technique  primarily used for imaging the anatomy  and 
associated  pathologies of the anterior segment (AS) of the eye.   UBM uses a higher frequency 
transducer (35-100 MHz) than conventional ultrasound. UBM has utility in diagnosis and 
management of uveitis. UBM is optional at sites that have access to the appropriate equipment . 
Both eyes should be imaged, according to the Schedule of Assessments.  
7.[ADDRESS_374317] ion of aqueous humor samples is not required from subjects 
randomized to Arm 5 (sham treatment) following the unmasking of the study. 
Aqueous humor samples may be analyzed for levels of aflibercept, .  
Remainin
g samples will be analyzed for additional biomarkers. 
7.10.[ADDRESS_374318] consents,  an optional vit reous humor sample 
can be obtained.  Vitreous humor samples will be analyzed primarily for aflibercept 
concentrations. If any other surgical procedures become medically necessary in the study and/or fellow eye during the course of the study, other ocular tissues may be provided, including aqueous or vitreous humor and lens to be analyzed for other biomarkers. The remaining samples may be analyzed for other biomarkers.   
8.0 REQUIRED, C ONCOM
 ITANT AND EXCLUDED MEDICATIONS  
8.1 Required Medications 
8.1.1   
 
8.1.2 Eylea® (aflibercept)  
Eylea (aflibercept) is indicated for the treatment of patients with DME ; it is co mmercially 
available (Eylea  USPI ). 
50 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374319]’s end of study or early 
termination visit.  
At the discretion of the evaluating physician, subjects m ay continue to receive all medications 
and standard treatments administered for other conditions except for treatments noted in the 
exclusion criteria described above and as noted in the prohibited medications section below. 
Prohibited Medications and Trea tments  
The follow
ing medications are prohibited during the study: 
• Any systemic anti -VEGF age nt including bevacizumab 
• Systemic drugs known to cause macular edema ( e.g., fingolim od, tamoxifen, 
chloroquine/hydroxychloroquine)  
• Any anti-VEGF agent in the study eye other than the study drug or aflibercept IVT 2 mg, as 
defined in this
 protocol  
•  
 
• Systemi
c Immun osuppressive  drugs (e.g., intravenous steroids, methotrexate, azathioprine, 
cyclosporin, adalimumab, infliximab, etanercept).  Inhaled or topi[INVESTIGATOR_305803] s 
are allowed  
• Use of any other investigational study treatment or device 
Note:  Subje
cts who develop high- risk PDR i n the study eye may receive panretinal 
photocoagulation (PRP)  after receiving rescue  aflibercept . 
Note:  Subject s with visually significant cataract cannot be enrolled in the study but if a 
cataract develops during  the study, c ataract s urgery in the study eye may be performed if 
clinically indicated and is scheduled > 90 days after ADVM -022 administration and/or 
> [ADDRESS_374320] injection of aflibercept.   
Note:  Subjects who develop DME in the fellow (non-study) eye may receive standard of 
care therapy.  
51 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374321] study visit.  Between the time of informed consent and study 
treatment administration  on Day 1 , only AEs (non- serious and serious) assessed as related to 
study procedures should be reported.  Events that occurred after the informed consent but prior to Day [ADDRESS_374322] be followed until 
a) the end of the AE reporting period at [ADDRESS_374323] study visit or b) for any ongoing 
IMP related AEs and/or SAEs until they are considered resolved or stable.    
The Investigator should use appropriate judgment in ordering additional tests as necessary to monitor the
 resolution of events.  The Adverum Medical Monitor may request that certain 
SAE/AE be followed longer.  
However, any clinically significant safety assessment that is associated with DME shall not be 
reported as
 an AE or SAE, unless judged by [CONTACT_305823]’s condition.  Progression of the disease under study will be captured as an efficacy 
outcome. 
9.[ADDRESS_374324] regardless of its causal 
relationship
 to the IMP  including but not limited to: 
• Any new disease or exacerbation of an existing condition 
• Conste
llations of individual signs, symptoms a nd laborat ory values should be reported as the 
underlying  diagn osis when possible (e.g., elevated WBC , cough and fever associated with 
pneumonia should not be reported as individual AEs but rather as the un ifying  condition of 
pneumonia) 
• Recurrence of a sporadic medical condition (e.g., fever) not present at Baseline  
• Adverse
 events related to a protocol-mandated intervention, including those that occur prior 
to study tre
atment (e.g., aflibercept injection) 
9.[ADDRESS_374325], regardless of its causal 
relationship
 to the ADVM -022, that results in:  
• death  
52 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374326]  2021 
 CONFIDEN TIAL  Page 53 of 74 • a life -threatening condition 
• inpatient hospi[INVESTIGATOR_1081] 
• persiste
nt or significant disability or incapacity or is a congenital anomaly or birth defect  
Import
ant medical events that may not meet these criteria may be considered SAEs when, based 
on approp
riate medical judgment, they may jeopardize the subject or may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.   
9.[ADDRESS_374327] (Immediately reportable to Sponsor)  
Adverse
 events of special interest for this study are as follows: 
• Sight-threatening adverse events: An adverse event is considered to be sight-threatening and 
should b
e reported expeditiously if it meets one or more of the following criteria:  
– It causes a decrease of ≥ 30 letters  in BCVA compared with the prior visit  
– It requires surgical or medical intervention (i.e., conventional surgery, vitrectomy) to 
prevent pe
rmanent loss of sight  
– It causes severe intraocular inflammation (i.e., endophthalmitis, 4+ anterior chamber 
cell/flare,
 or 4+ vitreous cells)  
All of the above -listed si ght-threatening adverse events should be reported as serious adverse 
events, listing the underlying cause (if known) of the event as the primary event term. 
9.[ADDRESS_374328] be recorded on a clinical study pregnancy form; the form must b
e sent to CRO within [ADDRESS_374329] be followed-up to determine outcome (including spontaneous miscarriage, elective termination, normal birth, or congenital abnormality) and status of mother and child, even if the subject withdrew.   
Any pregnancy complication and elective terminations for medical reasons must be reported as 
an AE or SAE
.  Spontaneous miscarriage must be reported as an SAE.  Any SAE occurring in 
association with a pregnancy, brought to the Investigator’s attention after the subject has completed the study, and considered by [CONTACT_305824].   
53 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374330] non-leading question to elicit any 
medically related 
changes in their well-being; and if they have been hospi[INVESTIGATOR_057], had any 
accidents, used any new medications, or changed concomitant medication regimens (prescription and OTC).   
9.[ADDRESS_374331] udy data (e.g., laborator y values, PE findings, ophthalmic 
examination) for from review of other documents relevant to subject safety during the study are 
to be documented on the AE eCRF.  Information to be collected includes event term, time of onset; Investigator assessment of seriousness, severity, and relationship to ADVM- 022; time of 
resolution of the event; any required treatment or evaluations; and outcome.  An AE resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to co ncurrent medications, 
or progression of comorbidities must be reported.  All AEs are to be followed to adequate 
resolution.  The Medical Dictionary for Regulatory Activities (MedDRA) will be used to code all AEs.   
Any medical condition that is present at the time that t
 he subject is screened but does not 
deteriorate should not be recorded as an AE.  However, if it deteriorates at any time during the 
study, it should be recorded as an AE. 
Any SAE or AE of Special Interest must be reporte d to the Sponsor or its designee immediately 
e.g., within [ADDRESS_374332] information is to be used for SAE reporting: 
CRO : Contact [CONTACT_305825]:  
 
 
Fax:  
 
 
Email:  
 
Prompt notification of SAEs by [CONTACT_305826]/ CRO is essential so th at legal and 
ethical responsibilities towards the safety of subjects are m et.   
54 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
-
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374333]  2021 
 CONFIDEN TIAL  Page 55 of 74 Adverum/ CRO  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of ADVM-022.  Adverum/ CRO will comply with country -
specific regulatory requirements relating to safety reporting to the regulatory authority, IRB, and 
Investigators.   
Investigator safety reports are prepared for suspected unexpected SAEs according to local 
regulatory r
equirements and Adverum/ CRO policy and are forwarded to Investigators, as 
necessary.   
Any Investigator who receives an Investigator safety report describing an SAE or other specific safety info
rmation (e.g., summary or listing of SAEs) from Adverum/ CRO  is to file it with the 
IRB and notify the IRB, if appropriate according to local requirements.   
9.[ADDRESS_374334]’s daily 
activities.
  The intensity of the AE will be rated on the following scale: 
Mild : The AE is noticeable but does not significantly impair the subject’s daily activities.  
Moderate:
 the AE reduces or impairs normal daily activity but is not incapacitating.  
Severe:  the AE is incapacitating and results in an inability to perform normal daily activity.   
Changes in t
he severity of an AE should be documented to allow an assessment of the duration 
of the event
 at each level of severity.  AEs characterized as intermittent do not require 
documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
9.[ADDRESS_374335]
igator’s assessm ent of rel ationship of an AE to study treatment is part of the 
documentation process, but it is not a factor in determining what is or is not reported.  If there is 
any doubt as to whether a clinical observation is an AE, the event is to be reported. 
Inves tigator should assess potential causes of each adverse event and events should be 
considered related if there is “a reasonable possibility of a causal relationship ” rather than if “a 
causal relationship cannot be ruled out .”  When assessing causality, Investigators shoul d assess 
biological balancing — the probability that the suspect drug caused the Adverse Event (AE) 
must be weighed against the probability that an alternative candidate caused it.  The  relationship 
or association of study treatment in ca using or contributing to the AE is to be characterized using 
the following classification and criteria:  
55 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374336]  2021 
 CONFIDEN TIAL  Page 56 of 74 Definitely 
Related :  A definite causal relationship exists between the study treatment  and the 
AE; including a plausible time relationship to study treatment , and it 
cannot be explained by [CONTACT_305827]/ 
exposures. 
Likely Related : There is a reasonable  possibility that study treatment  caused the adverse 
event; the event is unlikely  attributed to underlying or concurrent disease 
or other drugs/exposures (i.e., alternative explanation).  There is a 
reasonable time sequence to administration of the study drug. 
Unlikely Related : Underlyin g or concurrent disease or other drugs/exposures provide 
plausible alternative explanations.  Temporal relationship to study treatment administration makes a causal relationship improbable.  
Not Related : There is no association between the study treatment  and the reported 
event; there is a clear alternative explanation; a causal relationship is non -
plausible .  
 9.[ADDRESS_374337] be promptly reported to the Medical 
Monitor.  An overdose without signs or symptoms is not to be recorded as an AE; any AEs 
associated with the overdose is to be reported on the eCRF.   There is no specific antidote for 
overdose of study treatment.  In the event of a suspected overdose, it is recommended that supportive clinical care be instituted as considered  appropriate by [CONTACT_737], based on the 
subject’s clinical symptoms.  
10.[ADDRESS_374338] endpoints refer to pre -treatment 
measurements taken on the Day 1  visit when aflibercept I VT or Sham ocular injection  was 
administered.    
56 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374339]  2021 
 CONFIDEN TIAL  Page 57 of 74 • BCVA – Vision will be assessed primarily through the BCVA expressed as an ETDRS score 
(number of letters correctly read).  Maintenance of vision is classified if the subject has lost fewer than [ADDRESS_374340] 15 letters compared to 
Baseline, and the percent losi ng 15 or more letters compared to Baseline.  
• Central subfield 
 thickness – SD -OCT  will be performed using approved equipment and 
standard techniques to evaluate thickness and fluid compared to Baseline values.   Endpoints 
will include CST and macular volume and be assessed by [CONTACT_305828]. 
• Aflibercept re -treatmen ts – The incidence and timing of aflibercept injections given post 
ADVM -022 treatment over time.  
• For each timepoint, DRSS will be determined by [CONTACT_305829] -wide  
field c
olor fundus photography and compared to Day 1.   
• Vision threatening complication s (anteri or segment neovascularization, diabetic macular 
edema, high-risk PDR development, vitreous hemorrhage, or tractional retinal detachment) as determined by [CONTACT_153535] -wide field imaging and clinical examination by [CONTACT_737]. 
11.0 STATISTICAL CONSIDERATIONS 
11.1 Sample Si
ze Determ ination  
The durability of ADVM -022 will pr imarily be assessed through evaluation of the need for 
rescue aflibercept (2  mg I VT) due to worsening of DME disease activity .   Disease activity and 
rescue aflibercept (2  mg IVT) received will be summarized descriptively.  However, with 12 
subjects at a given dose level of ADVM-022 versus 9 subjects receiving aflibercept only (Control ), there is a 93.1% power for a [ADDRESS_374341] at an alpha level of 0.05 to 
claim a significant reduction in the rate (in terms of proportion of subjects) of disease worsening (or of receiving any rescue aflibercept 2 mg IVT) during a given follow-up time (say, 24, or 48 
weeks) when the true rate is 90% for the Control and 20% for the ADVM- 022 treated.  Table  5 
summarizes th
e powers for the same hypothesis tests under several different assumptions in the 
rate of receiving any aflibercept injection.  
57 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374342]  2021 
 CONFIDEN TIAL  Page 58 of 74 Table  5: Power for [ADDRESS_374343] Tests at Various Rate Assumptions  
Sample Size a Rate:  
Control  Ra te: 
ADVM -022 Tre
ated Power b 
(1-sided Fisher Exact,  
α = 0.05) 
N=12 ADVM -022 Treated  
versus  
N=9 Control  90% 17% 95.3%  
20% 93.1%  
25% 88.3%  
95% 17% 98.6%  
20% 97.7%  
25% 95.5%  
N=6 ADVM -022 Treated 
versus  
N=9 Control  90% 17% 88.8%  
20% 85.6%  
25% 79.6%  
95% 17% 95.2%  
20% 93.2%  
25% 89.0%  
a The sample sizes are not adjusted for dropouts.  
b Power for the Fisher Exact test was based on binomial enumeration of all possible outcomes, which was 
performed using PASS [ADDRESS_374344] event, the 95% upper confidence 
limit of the event rate is 11.7% for a group size of 24 (the target number of subjects to receive 
ADVM -022), or 22.1% for a group size of 12 (the target number of subjects to receive each dose 
level of ADVM -022).  
11.2 Analysis Populations  
The main 
analysis population will include  all rand omized subjects who receive the study 
treatmen t on Day 8 (ADVM -022 IVT or Sham ocular injection).  The summary  will be  based on 
the actual treatment received by [CONTACT_423] . 
11.[ADDRESS_374345] deviation (SD), median and range will be provided for continuous variables; and frequency counts and percentages will be provided for categorical variables .  Confidence interval s of the means and percentages  will be 
provided at both 90% and 95% levels .  Kaplan -Meier survival analysis will be utilized to derive 
median time to the first occurrence of DME disease worsening.  All  rescue aflibercept (2  mg 
IVT)  received by [CONTACT_305830].  Mean cumulative function (MCF) curve over time will be plotted for the mean cumulative number of injections.  Mixed -effect models for repeated  measures (MMRM) will be 
58 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374346] on DRSS changes over time will be explored using generalized mixed  models 
for categorical outcomes.    
An interim analys is (IA) is p lanned after all subjects have been followed for 24 weeks.  The 
detailed IA plan will be described in the Statistical Analysis Plan (SAP).   As unmasking of all 
subjects has occurred prior to the end of the study, the study in effect has become an open -label 
study.   
12.[ADDRESS_374347]  / Ins titutional Biosafety Committee  
Federal regulations and the ICH guidelines require that approval be obtained for each clinical site 
from an IRB/IB
C before participation of human sub jects in research studies.  Before study onset, 
the protocol, informed  consent form, and any other written information regarding this study to be 
provided to the subject or the subject’s legal guardian must be approved by [CONTACT_941] I RB/IBC, and 
written confirmation of such approval must be received by [CONTACT_779].  Documentation of all approvals and of the I RB/IBC compliance with ICH Guideline for Good Clinical Practice (E6) 
will be maintained by [CONTACT_305831]. 
All a pprovals should be signed by [CONTACT_1201]/IBC chair or designee and must identify the IRB /IBC 
by [CONTACT_2300] a
nd address, the clinical protocol by [CONTACT_11777], and the date 
approval or favorable opi[INVESTIGATOR_11744].  
12.[ADDRESS_374348] their origin in 
the Decla
ration of Helsinki  and Council of International Organizations of Medical Sciences 
(CIOMS) Ethical Guidelines, and in accordance w ith the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) , 
Harmonised Tripartite Guideline E6: Good Clinical Practice; 21 Code of Federal Regulations 
(CFR); and applicable laws and regulations. 
This s tudy will be conducted in compliance with the protocol approved by [CONTACT_941] I RB/IBC, a nd 
according to GCP standards.  No deviation from the protocol will be implemented without the prior review and approval of the Sponsor and the IRB, except where it may be nec essary to 
eliminate an immediate hazard to a subject enrolled in this study.  In such case, the deviation will be reported to the IRB as soon as possible. 
59 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374349] comply w ith the Decla ration of 
Helsinki, US Title  21 Code of Federal Regulations (CFR) Part 50, Health Insurance Portability 
and Accountability Act of 1996 ( HIPAA) (if applicable), and local laws.  The Investigator will 
draft the ICF , assent, and HIPAA authorization (if applicable) and submit the draft for review 
and comment by [CONTACT_1034], and Investigator will submit the mutually agreed upon ICF, ascent, 
and HIP AA authorization (if applicable) to the IRB/IBC for approval.   
The Inve stigator or designee (designee listed on the Delegation of Responsibilities log) must 
explain i
n terms understandable by [CONTACT_305832], procedures, anticipated benefit, potential risks, possible AEs, and any discomfort that participation in the protocol may entail.   This process must be documented in the 
subject’s source record.  Each subject or legally acceptable representative must be allowed to 
read the ICF under conditions where there is adequate time to consider the risks and benefits 
associated with participation.   
Before any study- specific
  procedure or test is performed, the Investigator must be certain that the 
subject or legally acceptable representative understands the implicati ons of participation in the 
study.  The subject or legally acceptable representative and the Investigator must sign and date 
the ICF before such subject is entered into the trial.  The I nvestigator is to retain the signed ICF 
and give a copy of the signed form to the subject or legally acceptable representative.  The process of obtaining informed consent is to be documented in the subject’s records. 
The Investigator or designee shall maintain a log of all subjects who have signed the ICF, or 
whose lega
lly acceptable representative has signed the ICF; and indicate whether the subject was 
enrolled or the reason for non- enrollment.  
If the ICF is revised during the course of the study, any institution- specific mod ifications 
proposed by [CONTACT_305833].  
13.0 INVESTIGATOR’S RESPONSIBILITIES  
A complet
e list of I nvestiga tor responsibilities is outlined in the Clinical Trial Agreement and the 
Statement of Investigator Form FDA 1572, both of which are signed by [CONTACT_305834].  In summary, the Investigator will conduct the study according to the current protocol, the Statement of Investigator, the general investigational plan, and applicable laws and regulations; will read and understand the Investigator’s Brochure; will obtain IRB/IBC approval to conduct the study; will obtain informed consent from each study participant prior to their participation in the study; will maintain and supply to the Sponsor or designee, auditors, and regulatory agencies adequate and accurate records of study activity and drug accountability for study- related monitoring, audits, IRB/IBC reviews and regulatory inspections; 
will report SAEs to the Sponsor or designee and IRB/IBC according t o the specifics outlined in 
60 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374350]  2021 
 CONFIDEN TIAL  Page 61 of 74 this protocol, which reports shall include an assessment of whether there is a reasonable 
possibility that the study drug caused the AE ; will personally conduct or supervise the study; and 
will ensure that colleagues participati ng in the study are informed about their obligations in 
meeting the above commitments. 
14.[ADDRESS_374351] be approved by [CONTACT_1201]/IBC before any subject can be enrolled into 
an amended protocol.  
14.2 Protocol Deviations 
A protocol d
eviation is any change, divergence, or de parture f rom the procedures and processes 
as specified in the protocol.  A significant protocol deviation occurs when there is nonadherence to the protocol that might significantly (a) impact the completeness, reliability, and/or accuracy of the study data , or (b) affect a subject’s rights, safety, or well-being.  The Investigator or 
designee must document and explain any protocol deviation in the subject’s source documentation.  Any significant protocol deviation will be investigated and reported by [CONTACT_305835], termination of the 
Investigator’s participation in the study, and/or other actions. 
The Sponsor or designee will be notified of known significant protocol deviations by [CONTACT_305836]. Protocol deviations found throughout the course of monitoring visits are to be 
documented by [CONTACT_24653].  The IRB/IBC should be notified of all applicable protocol deviations, i n accordance with reporting requirements of the IRB/IBC, in a timely manner by [CONTACT_3786].  
14.[ADDRESS_374352] comply with all applicable privacy laws and regulations (e.g., HIPAA).  
Informati
on on maintaining subject confidentiality in accordance with individual local and 
national subject privacy regulations must be provided to each subject as part of the informed consent process, either as part of the ICF or as a separate signed document.  In the [LOCATION_002], 
61 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374353]’s protected health information obtained during the study may be disclosed to the Sponsor and its designees, regulatory agencies, and the IRB/IBC.  
It is the Investigator’s or designee’s responsibility to obtain written permission to use protected 
health info
rmation from each subject.   If a subject withdraws permission to use protected health 
information, it is the Investigator’s responsibility to obtain the withdrawal request in writing from the subject and to ensure that no further data will be collected from the subject or used or disclosed except as necessary to protect the integrity of the study.  Any data collected on the subject before withdrawal will be used by [CONTACT_2728] (and/or its designees) in the analysis of study results to protect the integrity of the study.  During the review of source documents by [CONTACT_118106], the confidentiality of the subject will be respected in accordance with applicable professional standards and regulations.  
14.4 Investigato
 r’s Report to the IRB/IBC  
The Investigator is responsible for providing written summaries of the progress and status of the study at int
ervals not exceeding 1 year or otherwise specified by [CONTACT_1201]/IBC.  
Upon completion of the study, the Investigator, where applicable, should submit to the IRB/IBC the summar
y of the study outcome.  
14.[ADDRESS_374354] approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region; or until at least [ADDRESS_374355] 
elapsed since the form al discontinuation of clinical development of the ADVM -022.  These 
documents should be retained for a longer period if required by [CONTACT_67836].  It is the responsibility of the Sponsor to inform the Investigator or institution as to when these documents no longer need to be retained. 
14.6 Financial Disclosure and Obligations  
A separate fi
nancial agreement will be made between each Investig ator and the Sponsor or its  
authorized representative. For thi s study, each principal I nvestigator and sub-I nvestigator (as 
designated on the Form FDA 1572) will provide a personally signed Financial Disclosure Form 
in accordance with [ADDRESS_374356] of 
the study and for 1 year after the study has been completed.  
62 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374357]’s disease.  
14.[ADDRESS_374358] or injury, appropriate medical care as determined by [CONTACT_30780]/de
signee will be provided.  The ICF will include a description of treatment in the event 
of a protocol-related injury and handling of the costs associated therewith, incorporating country- specific national regulations and  / or local laws.  Allocation of financial responsibility as 
between Sponsor and each individual participating site for the costs associated with such treatment will be as specified in the relevant CTA.  Financial compensation for the lost wages, disability, or discomfort due the treatment with the ADVM -[ADDRESS_374359] copi[INVESTIGATOR_305804]. 
63 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374360]  2021 
 CONFIDEN TIAL  Page 64 of 74 15.2 Data Quality Assurance  
The Sponsor shall implement and maintain quality control and quality assurance procedures to 
ensure that 
the study is conducted, and that data are generated, documented, and reported in 
compliance with the protocol, GCP, and applicable regulatory requirements.  This study shall be conducted in accordance with the provisions of the Declaration of Helsinki (October 2013) and all revisions thereof, and in a ccordance with the FDA regulations (21 CFR Parts  11, 50, 54, 56, 
and 312, Subpart D—Responsibilities of Sponsors and Investigators) and with the ICH guidelines on GCP (ICH E6). 
15.[ADDRESS_374361] treated with the study drug. 
The Investigator or other study personnel will enter information from the source documents onto 
case report f
orms (CRFs) that will be used to collect the clinical study data.  A CRF must be 
completed for each enrolled subject with all required study data accurately recorded such that the information matches the data contained in medical records ( e.g., physicians’ note s, nurses’ notes, 
clinic charts, and other study- specific source documents).  
Authorized study site personnel ( e.g., liste
 d on the Delegation of Authority log) will complete 
CRFs designed for this study according to the completion guidelines that will be p rovided.  The 
Investigator will ensure that the CRFs are accurate, complete, legible, and completed within a reasonable period of time.  At all times, the Investigator has final responsibility for the accuracy and authenticity of all clinical data.  The CRFs exist within an electronic data capture (EDC) 
system with controlled access managed by [CONTACT_147489].  
Study staff will be appropriately trained in the use of CRFs and application of electronic 
signatures b
efore the start of the study and before being given access to the EDC system.  
Original data and any changes of data will be recorded using the EDC system, with all changes tracked by t
he system and recorded in an electronic audit trail.  The Investigator a ttests that the 
information contained in the CRFs is true by [CONTACT_36100].  
After database lock, the Investigator will receive a copy of the subject data ( e.g., paper, CD, or
  
other appropriate media) for archiving at the study site.  
64 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374362] exited the 
protocol for
 any reason, or the protocol is terminated at the sponsor’s discretion, whichever 
occurs first.  
The Sponsor has the ri ght to termin ate this study at any time at its discretion.  In terminating the 
study, the Sponsor and the Investigator will assure that adequate consideration is given to the protection of the subjects’ interests.  
65 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.   ADVM -022 (AAV.7m8 -aflibercept)  
Clinical Protocol No. ADVM -022-[ADDRESS_374363]  2021 
 CONFIDENTI AL Page 66 of 74 17.0 REFERENCES  
Dalkara D, By[CONTACT_305837], Klimczak RR, et al. In vivo-directed evolution of a new adeno- associated 
virus fo
r therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 
2013;5(189):189ra76. 
  
Eylea® Prescribing Information , Regeneron Pharmaceuticals, Inc. Tarrytown, NY. 
Grishanin R, Vuillemenot B, Sharma P, et. al. Preclinical Evaluation of ADVM -022, a Novel 
Gene T
herapy Approach to Treating Wet Age- Related Macular Degeneration. Molecular Ther . 
2019 Jan 2;27(1):118-129. 
Johnston SS, Wilson K, Huang A, et al.  Retrospective Analysis of First -Line Anti- Vas cular 
Endothelial Growth Factor Treatment Patterns in Wet Age -Related Macular Degeneration. Adv 
Ther. 2013;30:1111–1127. DOI 10.1007/s12325-013-0078-4. Varma R, Bressler NM, Doan QV, et al.  Prevalence of and Risk Factors f or Diabetic Macu
 lar 
Edema in the [LOCATION_002]. JAMA Ophthalmol. 2014;132(11):1334-1340. Wang W and Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. International 
Jour
nal of Molecular Sciences . 2018;19(1816).  
Wubben, TJ and Johnson MW. Anti- Vascular End othelial Growth Factor Therapy for Diabetic 
Retinopathy: Consequences of Inadvertent Treatment Interruptions. American J Ophthal . 
2019;204:13–18. https://doi.org/10.1016/j.ajo.2019.03.005   
66 of 74 CONFIDENTIAL______________________________________________________________________________________________ADVM-022 (AAV.7m8-aflibercept)
Protocol No. ADVM-022-04 (Amendment 7.0)______________________________________________________________________________________________
IND 019849 / Sequence No. 0018Adverum Biotechnologies, Inc.
... 